Science News
from research organizations

Efmoroctocog alfa for hemophilia A: Added benefit not proven

Study pool incomplete, information on results insufficient

Date:
April 4, 2016
Source:
Institute for Quality and Efficiency in Health Care
Summary:
Regarding Efmoroctocog alfa for hemophilia A, reviewers found that no added benefit can be derived. Type A hemophilia is an inherited disorder that impairs blood clotting.
Share:
FULL STORY

Efmoroctocog alfa (trade name: Elocta) has been approved since November 2015 for people with type A hemophilia. This is an inherited disorder that impairs blood clotting. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy both in prevention and in on-demand treatment. Such an added benefit cannot be derived from the dossier, however, because it contained no study data adequate for the research question.

Historical comparison: study pool incomplete

According to the Federal Joint Committee (G-BA), the new drug was to be compared with a recombinant or human plasma-derived coagulation factor VIII drug as appropriate comparator therapy. The drug manufacturer presented no data for such a direct comparison, however.

Instead, the dossier contained an unadjusted historical comparison on prophylactic treatment only. Data from a study on efmoroctocog alfa were compared with data from seven studies on the comparator therapy. A simplified search conducted by IQWiG showed that the study pool was incomplete. This was caused by an erroneous and incomplete search by the manufacturer for studies on the comparator therapy; no search at all was conducted in trial registries.

Information inadequate for benefit assessment

In addition, the data were inadequate. On the one hand, the manufacturer did not implement its own research question for the appropriate comparator therapy: It narrowed the inclusion criteria regarding the study population and the comparator therapy in such a way that patients under twelve years of age and studies on human plasma preparations were not included, for example. On the other, it only considered two outcomes: the number of annual bleeding events and the use of factor VIII preparations. However, all available results on patient-relevant outcomes from the four categories "mortality," "morbidity," "health-related quality of life" and "adverse events" are to be considered in a benefit assessment.

Hence an added benefit of efmoroctocog alfa in comparison with the appropriate comparator therapy is not proven.


Story Source:

Materials provided by Institute for Quality and Efficiency in Health Care. Note: Content may be edited for style and length.


Cite This Page:

Institute for Quality and Efficiency in Health Care. "Efmoroctocog alfa for hemophilia A: Added benefit not proven: Study pool incomplete, information on results insufficient." ScienceDaily. ScienceDaily, 4 April 2016. <www.sciencedaily.com/releases/2016/04/160404111521.htm>.
Institute for Quality and Efficiency in Health Care. (2016, April 4). Efmoroctocog alfa for hemophilia A: Added benefit not proven: Study pool incomplete, information on results insufficient. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2016/04/160404111521.htm
Institute for Quality and Efficiency in Health Care. "Efmoroctocog alfa for hemophilia A: Added benefit not proven: Study pool incomplete, information on results insufficient." ScienceDaily. www.sciencedaily.com/releases/2016/04/160404111521.htm (accessed May 23, 2017).

RELATED STORIES